A toddler diagnosed with severe postinfectious bronchiolitis obliterans and COVID-19 infection

Area of Science:

• Pediatric Pulmonology
• Infectious Diseases
• Critical Care Medicine

Background:

• Management of SARS-CoV-2 in children with chronic lung disease presents challenges due to limited research on respiratory comorbidities beyond asthma.
• Low general pediatric morbidity and incidence of specific pulmonary conditions contribute to a scarcity of studies in this demographic.
• Antiviral treatment, such as remdesivir, shows promise in adults and small pediatric cohorts, but its efficacy and safety in children with diverse respiratory conditions require further investigation.

Discussion:

• This report details a 3-year-old toddler with severe postinfectious bronchiolitis obliterans who contracted COVID-19.
• The patient received a 5-day course of remdesivir on a compassionate use basis.
• The case explores the potential benefits of antiviral therapy in a pediatric patient with significant underlying pulmonary pathology.

Key Insights:

• Compassionate use of remdesivir was associated with a favorable outcome in a pediatric case of COVID-19 with severe postinfectious bronchiolitis obliterans.
• This case adds to the limited evidence regarding antiviral treatment for children with complex respiratory conditions and SARS-CoV-2 infection.
• The study underscores the need for further evaluation of remdesivir's safety and efficacy in pediatric populations with underlying lung disease.

Outlook:

• Further research is warranted to establish the safety and efficacy of remdesivir in pediatric patients with various respiratory comorbidities.
• Clinical trials are needed to determine optimal dosing, duration, and patient selection for antiviral therapy in this population.
• Understanding the pathophysiologic impact of COVID-19 on children with chronic lung disease will guide future treatment strategies.